| Oct 4 |
Pharma Stock Roundup: FDA Approves SNY's Dupixent for COPD & More
|
| Oct 4 |
AbbVie Cuts 2024 Earnings Guidance to Include Acquisition Costs
|
| Oct 4 |
Thermo Fisher plant making Astra/ Sanofi RSV drug reportedly breached FDA rules
|
| Oct 4 |
How to minimise a capital gains tax impact on your investments
|
| Oct 3 |
AstraZeneca Seeks Expanded Use For Blood Cancer Drug Calquence, FDA Grants Priority Review
|
| Oct 3 |
AstraZeneca's Calquence sNDA Gets FDA Priority Tag for Expanded Use
|
| Oct 3 |
AstraZeneca supplemental NDA for Calquence accepted by FDA
|
| Oct 3 |
U.S. tweaks 2025 Medicare price negotiation process
|
| Oct 3 |
AstraZeneca Says Calquence Granted FDA Priority Review in Mantle Cell Lymphoma
|
| Oct 3 |
CALQUENCE® (acalabrutinib) granted Priority Review in the US for patients with untreated mantle cell lymphoma
|
